Welcome to our dedicated page for Clearmind Medici SEC filings (Ticker: CMND), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical-stage biotech filings rarely read like light bedtime material鈥攁nd Clearmind Medicine鈥檚 SEC disclosures are a case in point. Updates on MEAI trial cohorts, patent issuances across 19 families, and at-the-market financing terms are scattered through 200-page documents. If you have ever wondered, 鈥淗ow do I find Clearmind鈥檚 latest 10-K without digging for hours?鈥� or searched for 鈥淐learmind Medicine insider trading Form 4 transactions,鈥� this page is built for you.
Stock Titan鈥檚 AI breaks down each document the moment it hits EDGAR. Whether you open a Clearmind Medicine quarterly earnings report 10-Q filing, a sudden 8-K material event explained, or a Schedule 14A proxy statement on executive compensation, our engine highlights trial milestones, cash runway shifts, and warrant repricings in plain language. AG真人官方-time alerts flag Clearmind Medicine Form 4 insider transactions鈥攕o you can spot executive stock moves before the market digests them.
Inside each filing you will also find:
- Side-by-side revenue and R&D spend trends from successive reports for quick quarter-over-quarter comparisons
- Automatic extraction of newly granted patents protecting MEAI and other pipeline assets
- Contextual notes that translate complex risk-factor language into actionable insights
Stop downloading endless PDFs. From 鈥渦nderstanding Clearmind Medicine SEC documents with AI鈥� to tracking 鈥淐learmind Medicine executive stock transactions Form 4鈥� in real time, every regulatory detail is summarized so you can focus on decisions, not deciphering. Complex biotech filings, simplified.
AdvisorShares Trust has filed a Schedule 13G revealing a passive ownership stake in the Invesco S&P International Developed Low Volatility ETF, a series of Invesco Exchange-Traded Fund Trust II. As of 30 June 2025, the Delaware-domiciled trust beneficially owned 1,171,328 shares, equating to 9.68 % of the ETF鈥檚 outstanding units. The filer reported sole voting and sole dispositive power over the entire position, with no shared authority.
The disclosure was filed under Rule 13d-1(b)/(c)/(d), indicating the holding is passive and was acquired in the ordinary course of business鈥攏ot to influence control of the issuer. This is affirmed in the certification signed by Chief Compliance Officer Stefanie Little on 3 July 2025.
Crossing the 5 % threshold but remaining below 10 % obliges AdvisorShares to report via Form 13G while avoiding the more activist-oriented Schedule 13D. For market participants, the filing highlights meaningful institutional interest in the low-volatility international equity strategy but does not, on its own, signal any imminent strategic changes to the ETF or its holdings.
Clearmind Medicine Inc. (NASDAQ: CMND) filed a Form 6-K for June 2025. The filing mainly furnishes a press release dated 27 June 2025 entitled 鈥淐learmind Medicine Expands Global Clinical Trial Targeting Multibillion-Dollar Alcohol Use Disorder Market.鈥�
Key points disclosed:
- The company is expanding its global clinical trial program aimed at Alcohol Use Disorder (AUD), a market the company characterises as multibillion-dollar.
- The first four paragraphs of the press release are automatically incorporated by reference into Clearmind鈥檚 effective shelf registration statements on Form F-3 (File Nos. 333-275991, 333-270859, 333-273293) and its equity incentive Form S-8 (File No. 333-283695).
- No financial metrics, study data, or timelines are provided in the filing itself.
- The document is informational only; it does not request shareholder action nor announce financing.
The 6-K was signed by CEO Adi Zuloff-Shani on 27 June 2025.
Clearmind Medicine Inc. (CMND) has filed a Form 6-K for June 2025.
The filing mainly furnishes a press release dated 23 June 2025 entitled 鈥淐learmind Medicine Adds Leading Israeli Clinical Site to Its Ongoing Clinical Trial for Alcohol Use Disorder.鈥� No financial statements, earnings data, or transactional details accompany the report. The company simply notifies investors that the first two paragraphs of the press release are incorporated by reference into several existing U.S. registration statements on Forms F-3 (File Nos. 333-275991, 333-270859, 333-273293) and S-8 (File No. 333-283695).
The filing is signed by CEO Adi Zuloff-Shani on 23 June 2025. Aside from the clinical-site expansion disclosure, there are no other material events, financial metrics, or risk factors discussed.
On June 18, 2025, the U.S. Securities and Exchange Commission declared effective Clearmind Medicine Inc.鈥檚 post-effective amendment to its registration statement (Submission Type: POS AM, File No. 333-276913, Accession No. 0001213900-25-053898). This Notice of Effectiveness (Form EFFECT) confirms that the company鈥檚 shelf registration is now operative.
The filing contains no financial statements, earnings data, or details of securities to be immediately issued. It is a routine administrative step that gives Clearmind Medicine the legal authority to offer and sell the securities covered by the registration statement at a future date; it does not, by itself, change the company鈥檚 operations or financial position.
FAQ
What is the current stock price of Clearmind Medici (CMND)?
What is the market cap of Clearmind Medici (CMND)?
What does Clearmind Medicine Inc. specialize in?
What is MEAI and how is it used?
What is Clearmind鈥檚 approach to intellectual property?
Who are Clearmind鈥檚 key collaborators?
What market needs does Clearmind address?
How does Clearmind ensure safety in its treatments?
What is Clearmind鈥檚 alcohol alternative product?
What differentiates Clearmind from competitors?
